Acute and chronic complication profiles among patients with chronic kidney disease in Alberta, Canada: a retrospective observational study.
Humans
Renal Insufficiency, Chronic
/ epidemiology
Retrospective Studies
Male
Female
Middle Aged
Aged
Alberta
/ epidemiology
Comorbidity
Diabetes Mellitus, Type 2
/ epidemiology
Hypertension
/ epidemiology
Adult
Aged, 80 and over
Cardiovascular Diseases
/ epidemiology
Acute Disease
Atherosclerosis
/ epidemiology
Hospitalization
ASCVD
CKD
Comorbidities
Complications
Type 2 diabetes
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
05
06
2023
accepted:
20
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
Chronic kidney disease (CKD) poses a substantial burden to individuals, caregivers, and healthcare systems. CKD is associated with higher risk for adverse events, including renal failure, cardiovascular disease, and death. This study aims to describe comorbidities and complications in patients with CKD. We conducted a retrospective observational study linking administrative health databases in Alberta, Canada. Adults with CKD were identified (April 1, 2010 and March 31, 2019) and indexed on the first diagnostic code or laboratory test date meeting the CKD algorithm criteria. Cardiovascular, renal, diabetic, and other comorbidities were described in the two years before index; complications were described for events after index date. Complications were stratified by CKD stage, atherosclerotic cardiovascular disease (ASCVD), and type 2 diabetes mellitus (T2DM) status at index. The cohort included 588,170 patients. Common chronic comorbidities were hypertension (36.9%) and T2DM (24.1%), while 11.4% and 2.6% had ASCVD and chronic heart failure, respectively. Common acute complications were infection (58.2%) and cardiovascular hospitalization (24.4%), with rates (95% confidence interval [CI]) of 29.4 (29.3-29.5) and 8.37 (8.32-8.42) per 100 person-years, respectively. Common chronic complications were dyslipidemia (17.3%), anemia (14.7%), and hypertension (11.1%), with rates (95% CI) of 11.9 (11.7-12.1), 4.76 (4.69-4.83), and 13.0 (12.8-13.3) per 100 person-years, respectively. Patients with more advanced CKD, ASCVD, and T2DM at index exhibited higher complication rates. Over two-thirds of patients with CKD experienced complications, with higher rates observed in those with cardio-renal-metabolic comorbidities. Strategies to mitigate risk factors and complications can reduce patient burden.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) poses a substantial burden to individuals, caregivers, and healthcare systems. CKD is associated with higher risk for adverse events, including renal failure, cardiovascular disease, and death. This study aims to describe comorbidities and complications in patients with CKD.
METHODS
METHODS
We conducted a retrospective observational study linking administrative health databases in Alberta, Canada. Adults with CKD were identified (April 1, 2010 and March 31, 2019) and indexed on the first diagnostic code or laboratory test date meeting the CKD algorithm criteria. Cardiovascular, renal, diabetic, and other comorbidities were described in the two years before index; complications were described for events after index date. Complications were stratified by CKD stage, atherosclerotic cardiovascular disease (ASCVD), and type 2 diabetes mellitus (T2DM) status at index.
RESULTS
RESULTS
The cohort included 588,170 patients. Common chronic comorbidities were hypertension (36.9%) and T2DM (24.1%), while 11.4% and 2.6% had ASCVD and chronic heart failure, respectively. Common acute complications were infection (58.2%) and cardiovascular hospitalization (24.4%), with rates (95% confidence interval [CI]) of 29.4 (29.3-29.5) and 8.37 (8.32-8.42) per 100 person-years, respectively. Common chronic complications were dyslipidemia (17.3%), anemia (14.7%), and hypertension (11.1%), with rates (95% CI) of 11.9 (11.7-12.1), 4.76 (4.69-4.83), and 13.0 (12.8-13.3) per 100 person-years, respectively. Patients with more advanced CKD, ASCVD, and T2DM at index exhibited higher complication rates.
CONCLUSIONS
CONCLUSIONS
Over two-thirds of patients with CKD experienced complications, with higher rates observed in those with cardio-renal-metabolic comorbidities. Strategies to mitigate risk factors and complications can reduce patient burden.
Identifiants
pubmed: 39080608
doi: 10.1186/s12882-024-03682-z
pii: 10.1186/s12882-024-03682-z
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
244Informations de copyright
© 2024. The Author(s).
Références
Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, et al. Prevalence and demographics of CKD in Canadian Primary Care practices: a cross-sectional study. Kidney Int Rep. 2019;4(4):561–70.
doi: 10.1016/j.ekir.2019.01.005
pubmed: 30993231
pmcid: 6451150
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet (London England). 2013;382(9888):260–72.
doi: 10.1016/S0140-6736(13)60687-X
pubmed: 23727169
IHME. GBD Compare: health data org. 2019 [ https://vizhub.healthdata.org/gbd-compare/ .
Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–40.
doi: 10.1038/ki.2010.550
pubmed: 21289598
Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104.
doi: 10.1038/ki.2010.531
pubmed: 21289597
pmcid: 3959732
Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrology: JASN. 2013;24(9):1478–83.
doi: 10.1681/ASN.2012040392
pmcid: 3752941
Manns B, Hemmelgarn B, Tonelli M, Au F, So H, Weaver R, et al. The cost of care for people with chronic kidney disease. Can J Kidney Health Dis. 2019;6:2054358119835521.
doi: 10.1177/2054358119835521
pubmed: 31057803
pmcid: 6452586
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–50.
doi: 10.1001/jama.291.7.844
pubmed: 14970063
System USRD, USRDS Annual Data Report. 2020 : Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney Disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602–10.
doi: 10.1001/jama.2016.10924
pubmed: 27532915
pmcid: 5444809
Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012. BMJ open Diabetes Res care. 2016;4(1):e000154.
doi: 10.1136/bmjdrc-2015-000154
pubmed: 27110365
pmcid: 4838667
Nanna M, Sloan L, Faurby M, Husemoen LLN, Tombak G, Yerragolam D, et al. Abstract 11398: prevalence and characteristics of systemic inflammation in adults with atherosclerotic Cardiovascular Disease and chronic kidney disease: results from the National Health and Nutrition Examination Survey. Circulation. 2022;146(Suppl_1):A11398–A.
Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73.
doi: 10.1016/S0140-6736(12)61350-6
pubmed: 23013602
pmcid: 3771350
System USRD. USRDS 2010 Annual Data Report: Atlas of chronic kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
Sarnowski A, Gama RM, Dawson A, Mason H, Banerjee D. Hyperkalemia in chronic kidney disease: links, risks and management. Int J Nephrol Renovasc Dis. 2022;15:215–28.
doi: 10.2147/IJNRD.S326464
pubmed: 35942480
pmcid: 9356601
Hsu RK, Hsu CY. The role of Acute kidney Injury in chronic kidney disease. Semin Nephrol. 2016;36(4):283–92.
doi: 10.1016/j.semnephrol.2016.05.005
pubmed: 27475659
pmcid: 4979984
Dalrymple LS, Go AS. Epidemiology of Acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5).
Chang C-H, Fan P-C, Kuo G, Lin Y-S, Tsai T-Y, Chang S-W, et al. Infection in Advanced chronic kidney disease and subsequent adverse outcomes after Dialysis initiation: a Nationwide Cohort Study. Sci Rep. 2020;10(1):2938.
doi: 10.1038/s41598-020-59794-7
pubmed: 32076027
pmcid: 7031239
Syed-Ahmed M, Narayanan M. Immune Dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8–15.
doi: 10.1053/j.ackd.2019.01.004
pubmed: 30876622
Xanthopoulos A, Papamichail A, Briasoulis A, Loritis K, Bourazana A, Magouliotis DE et al. Heart failure in patients with chronic kidney disease. J Clin Med. 2023;12(18).
Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–80.
doi: 10.1016/S0140-6736(11)60178-5
pubmed: 21840587
Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156(8):570–81.
doi: 10.7326/0003-4819-156-8-201204170-00008
pubmed: 22508734
BC Guidelines and Protocols Advisory Committee. Chronic Kidney Disease - Identification, Evaluation and Management of Adult Patients. 2019.
Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALMDJP, Griffith KEHB, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3(1):1–150.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.
doi: 10.1016/S0140-6736(07)61602-X
Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inf Decis Mak. 2015;15:31.
doi: 10.1186/s12911-015-0155-5
Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3(1).
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.
doi: 10.1093/aje/kwq433
pubmed: 21330339
Tu JV, Khan AM, Ng K, Chu A. Recent temporal changes in atherosclerotic Cardiovascular diseases in Ontario: clinical and Health systems Impact. Can J Cardiol. 2017;33(3):378–84.
doi: 10.1016/j.cjca.2016.11.009
pubmed: 28129964
McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501–10.
doi: 10.1185/030079904X2763
pubmed: 15383200
Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13(3):199–204.
doi: 10.1053/j.ackd.2006.04.004
pubmed: 16815225
Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015;20(3):259–72.
doi: 10.1007/s10741-014-9460-9
pubmed: 25344016
Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(6):572–86.
doi: 10.1038/ki.2011.223
pubmed: 21750584
Global regional, national burden of chronic kidney disease. 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2020;395(10225):709–33.
doi: 10.1016/S0140-6736(20)30045-3
Crews DC, Novick TK. Social determinants of CKD hotspots. Semin Nephrol. 2019;39(3):256–62.
doi: 10.1016/j.semnephrol.2019.02.003
pubmed: 31054624
pmcid: 6508089
Banerjee T, Crews DC, Wesson DE, Dharmarajan S, Saran R, Ríos Burrows N, et al. Food Insecurity, CKD, and subsequent ESRD in US adults. Am J Kidney Dis. 2017;70(1):38–47.
doi: 10.1053/j.ajkd.2016.10.035
pubmed: 28215947
pmcid: 5765854
Tonelli M, Dickinson JA. Early detection of CKD: implications for Low-Income, Middle-Income, and high-income countries. J Am Soc Nephrol. 2020;31(9):1931.
doi: 10.1681/ASN.2020030277
pubmed: 32839279
pmcid: 7461685